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Background: To study the prevalence of Chlamydia infection in women with primary and secondary unexplained
infertility using ELISA technique for antibody detection and real time, fully automated PCR for antigen detection
and to explore its association with circulating antisperm antibodies (ASA).
Methods: A total of 50 women with unexplained infertility enrolled in this case control study and a control group
of 44 infertile women with a known cause of infertility. Endocervical specimens were collected for Chlamydia
antigen detection using PCR and serum samples for antibodies detection. Circulating anti-sperm antibodies were
detected using sperm antibody Latex Agglutination tests.
Results: The overall prevalence of Chlamydial infection in unexplained infertility cases as detected by both ELISA
and PCR was 40 % (20/50). The prevalence of current Chlamydial genital infection as detected by real-time PCR was
only 6.0 % (3/50); two of which were also IgM positive. Prevalence of ASA was 6.0 % (3/50); all were sero-negative
for anti-C.trachomatis IgM and were PCR negative.
Conclusion: The incidence of Chlamydial infection in Egyptian patients with unexplained infertility is relatively high.
In the setting of fertility investigations; screening for anti. C.trachomatis antibodies using ELISA, and treatment of
positive cases should be considered. The presence of circulating ASA does not correlate with the presence of old
or current Chlamydia infection in women with unexplained infertility.
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Unexplained infertility (UI) is a diagnosis that is reached
when all the standard investigations such as tests for ovu-
lation, tubal patency tests and semen analysis are normal
[1, 2]. The average incidence of unexplained infertility
varies from 0 % to 37 % [3]. Chlamydia trachomatis is the
most common sexually transmitted bacterial pathogen [4].* Correspondence: mohamedyoussef1973@gmail.com
1Department of obstetrics & gynecology, Faculty of Medicine, Cairo
University, Cairo, Egypt
3Egyptian International Fertility IVF-ET center, 16 Elhassan Ben Ali, Nast City,
Cairo, Egypt
Full list of author information is available at the end of the article
© 2015 Abdella et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.It is estimated that over 90 million cases occur annually
worldwide attesting to its public health importance. More
than two-thirds of these cases occur in the developing
world where diagnostic and treatment facilities are almost
absent [5].
C.trachomatis of the lower genital tract is predomin-
antly asymptomatic in men and women. Between one half
and two thirds of such infections in women remain
undetected and hence untreated, resulting in serious long-
term sequelae, such as ectopic pregnancy and tubal
infertility [6, 7]. Consequently, screening is necessary to
identify and treat this infection to help reduce duration of
infectivity, transmissibility and long term sequelae [8–10].l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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standard against which all other tests have been compared.
As culture methods are difficult to standardize, technically
demanding and expensive, other tests have been developed
[11]. Nucleic acid amplification techniques (NAAT) are
currently being used to diagnose chlamydial infections.
NAATs can be used with noninvasively collected speci-
mens, such as first-void urine samples (FVU) from men or
women and self- or clinician-collected vaginal swabs lead-
ing to increased acceptance of C. trachomatis screening
programmes among asymptomatic persons [12, 13].
Reliable estimates of prevalence data for genital Chla-
mydia infection using sensitive and specific techniques
like nucleic acid amplification tests are lacking in develop-
ing countries as Egypt. Few available reports describe an
increased incidence of genital Chlamydial infection, espe-
cially among symptomatic Egyptian women [14]. There is
an ongoing debate as to whether or not screening of all in-
fertile women and treatment of those found to be infected
is desirable or cost effective. Hence, the present pilot study
was designed to determine the prevalence of C.trachoma-
tis infection (past and current) in Egyptian females with
unexplained infertility using ELISA and real-time fully au-
tomated PCR (Real-TM PCR) and evaluate its association
with circulating anti-sperm antibodies.
Methods
From September 2013 to February 2014, we enrolled 50 in-
fertile couples with unexplained infertility seeking concep-
tion who attended the infertility outpatient clinic and the
Assisted Conception Unit at Cairo university hospital and
the Egyptian International fertility IVF – ET center (EIFC-
IVF), Cairo, Egypt. The study participants presented with
primary or secondary unexplained infertility for more than
2 years and were recruited from a total of 215 infertile
women examined. The study protocol was approved by
the Scientific and Ethical Committee of the Obstetrics and
Gynecology Department of Cairo University.
The diagnosis of unexplained infertility was based on:
documentation of ovulation by trans-vaginal ultrasonog-
raphy and normal mid-luteal serum progesterone levels,
documentation of normal uterine cavity by hysteroscopy,
bilateral tubal patency by hysterosalpingography/ laparos-
copy as indicated and normal semen parameters by WHO
criteria [15]. The exclusion criteria were: history of pelvic
surgery including cesarean section, history of pelvic
inflammatory disease and clinical features suggestive of
pelvic pathology such as, endometriosis, uterine fibroids
and ovarian cysts,previous use of intrauterine contracep-
tive device especially in cases with secondary infertility.
Later, we included a control group of 44 women pre-
senting with primary or secondary infertility either due to
male factor only with no identifiable female factor; women
with the diagnosis of PCO; menstrual irregularities and/oruterine fibroids. Those with evident tubal factor of infertil-
ity as diagnosed by hysterosalpingography and laparos-
copy or premature ovarian failure were excluded from the
control group as well as the previously mentioned exclu-
sion criteria for the cases. The need to include a control
group emerged when we were faced by the unexpectedly
high prevalence of Chlamydia trachomatis infection
among the first group of unexplained infertility cases and
due to the lack of previous studies in Egypt clearly
addressing this issue. A question was raised as to whether
this high prevalence is specific to cases of unexplained
infertility only or is it also a common finding in infertile
women without an evident tubal factor of infertility or
dense pelvic adhesions or endometriosis which are usually
conditions difficult to treat. An informed, written consent
was obtained from all participants prior to enrollment and
was written in the Arabic language.
Endocervical swabs were collected by the attending
physician. The swab was inserted into the endocervical
canal for a distance about 1-1.5 cm until most of the swab
tip was inside the external os. In nulliparous women,
swabs were inserted as far as could be reached. Swabs
were left in place for about 5–10 s while applying pressure
or scraping to obtain more cells from the endocervix and
were subsequently expressed in 5 ml of phosphate buffer
saline (PBS) transport medium for Chlamydial antigen de-
tection. The phosphate buffer saline (PBS) was prepared
as described by Dulbecco and VogtinSambrook et al. [16].
Detection of the C.trachomatis DNA in the collected
cervical specimens was done using the Real-TM PCR by
amplification. Real-TM PCR(TaqMantechnology, ABI
7500, AppliedBiosystems) was coupled with an automated
DNA extraction method (QIAGEN). Extraction of DNA
was performed using the QI Amp DNA mini kit (50)
(QIAGEN GmbH, Hilden, Germany Cat. No. 51304).
Primers and probe for Real-TM PCRassay were selected
from sequences of the cryptic plasmid (GenBank acces-
sion nos M19487, Y00505, J03321, X06707 and X07547)
of five different C. trachomatis strains (serotypes A, B, D,
L1 and L2, respectively), and designed using Primer
Express software (Applied Biosystems)). A forward primer
Ctr_F (59-CATGAAAACTCGTTCCGAAATAGAA-39),a
reverse primer Ctr_R (59TCAGAGCTTTACCTAACA
ACGCATA-39)(which amplify a 71 bp DNA segment of
C. trachomatis) and aminorgroove binder probe labeled
with 59FAM (6-carboxyfluorescein) Ctr_P (59TCGCATG
CAAGATATCGA-39) were selected. The melting tempe
rature (Tm) of the probe was chosen to be 10–11 °C higher
than that of the corresponding primers, in order to ensure
probe hybridization during primer extension. The primers
were prepared by Eurogentec and the probe by Applied
Biosystems. The reactions were performed in a final
volume of 20 μl, including 0.2 μM each primer, 0.1 μM
Ctr_P probe, 10 μl 26 TaqManUniversal Master Mix
Table 1 Comparison of the clinical and demographic
characteristics between the unexplained infertility cases
and the controls
Variable Cases (n = 50) Controls (n = 44) p-values
Age (yrs)* 30.78 (19-41) 30.68 (19-40) 0.893
Body mass index (kg/m2)* 30.26 ± 2.21 31.07 ± 1.69 0.211
Duration of Infertility (yrs)* 3.93 (2.5-10) 5.0 (2-16) 0.041
< 5 years 26 (52 %) 31 (70.5 %) 0.068
≥5 years 24 (48 %) 13 (29.5 %)
Type of infertility
Primary 36 (72 %) 35 (79.5 %) 0.396
Secondary 14 (28 %) 9 (20.5 %)
Previous parity 9 (18 %) 6 (13.6 %) 0.564
Previous abortion 10 (20 %) 6 (13.6 %) 0.413
Previous ICSI/IUI 17 (34 %) 9 (20.5 %) 0.308
Anti C.trachomatis IgM + ve 3/50 (6 %) 0/44 (0 %) 0.099
Anti C.trachomatis IgG + ve 18 (36 %) 8 (18.2 %) 0.054
Ratio of IgM* 0.37 ± 0.26 0.59 ± 0.24 < 0.05
Ratio of IgG* 1.26 ± 0.99 0.87 ± 0.63 0.03
PCR positive 3/50 (6 %) 0/44 (0 %) 0.09
Antisperm Abs positive 3/50 (6 %) 1/44 (2.3 %) 0.372
*Values are expressed in terms of mean ± S.D. Other values are expressed in
terms of frequency and %. S stands for significant (p < 0.05); NS stands
for non-significant
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tions were 2 min at 50 °C, 10 min at 95 °C, followed by
45 cycles of 15 s at 95 °C and 1 min at 60 °C. Amplification
and PCR product detection were performed with the ABI
Prism 7900 Sequence Detection system (Applied Biosys-
tems) [16].
Interpretation of the real-time TaqMan PCR was done
as follow; During amplification, the reporter dye (FAM)
was measured against the passive reference dye (ROX)
signal to normalize fluorescence fluctuations not related
to PCR amplification and that may occur with increasing
cycle numbers. A positive result was determined by
identifying the threshold cycle (Ct), i.e. the cycle number
at which normalized reporter dye emission was above
the background noise (corresponding to ten times the
standard deviation of the mean baseline emission calcu-
lated for PCR cycles 3–15). If the fluorescent signal did
not increase within 45 cycles, the sample was considered
negative [17].
Serodiagnosis for Anti-C.trachomatis IgG and IgM:
About 3-5 ml of peripheral venous blood samples were
collected for all patients and were allowed to stand to
clot. The serum was then separated by centrifugation.
The serum was examined using the ELISA Technique
(enzyme-linked immune-sorbent assay) for detection of
the anti-C.trachomatis IgG and IgM. The ratios of IgM
and IgG were also calculated. Detection of C. trachomatis
specific IgG and IgM by ELISA: Circulating anti C. tracho-
matis IgG antibodies were detected in serum by ELISA
(enzyme-linked immunosorbent assay) using RIDAS-
CREEN®Chlamydia trachomatis, KGM2901, R-Biopharm
Darmstadt, Germany) which provides materials for the
semi qualitatitive determination of IgG and IgM-classes
antibodies to C. trachomatis in serum. Specimen col-
lection, preparation, assay procedure, calculation and
interpretation of results were done according to the manu-
facturer's instructions.
The average absorbance is calculated for the cut-off con-
trol and the sample index (SI) is obtained by dividing the
absorbance for the sample by the calculated average value
of IgG & IgM as follows; negative, SI <0.9, equivocal, SI
0.9 to 1.1 and positive, SI >1.1. Blood for determination of
circulating Antisperm Antibody (ASA, IgG class) was
drawn. ASA in serum was assayed by Sperm Ab Latex
Agglutination tests (BIOSERV Diagnostics, R-Biopharm,
Germany) which were done according to the manufactur-
er's instructions. Results were communicated with the
patient and treatment in form of doxycycline 100 mg
twice daily for seven days was offered to the patient and
her partner on diagnosis.
Data were statistically described in terms of mean ±
standard deviation (± SD), median and range, or frequen-
cies (number of cases) and percentages when appropriate.
Comparison of numerical variables between the studygroups was done using Mann Whitney U test for inde-
pendent samples. For comparing categorical data, Chi
square (χ2) test was performed. Exact test was used instead
when the expected frequency is less than 5. Correlation be-
tween various variables was done using Pearson moment
correlation equation for linear relation in normally distrib-
uted variables and Spearman rank correlation equation for
non-normal variables. p values less than 0.05 was consid-
ered statistically significant. All statistical calculations were
done using computer program SPSS (Statistical Package
for the Social Science; SPSS Inc., Chicago, IL, USA) release
15 for Microsoft Windows (2006).Results
Ninety-four women consented to participate in this study;
a first group of 50 cases with unexplained infertility and a
control group of 44 women with a known cause of infertil-
ity. Both groups were comparable regarding the age and
BMI where the mean age (± S.D) of the cases group was
30.78 ± 5.81 years (range from 19 to 40 years) and for the
control group was 30.68 ± 6.11 years. The mean infertility
duration was 5 ± 3.19 years for the cases while it was
3.93 ± 1.62 years for the controls with a statistically signifi-
cant difference. Thirty-six out of 50 cases (72 %) had pri-
mary unexplained infertility and 14 out of 50 cases (28 %)
had the secondary type (Table 1). The mean gravidity was
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failed IUI (46 % of which were IgG + ve) and 6.0 % had a
failed ICSI trial (all were seronegative for anti- C.tracho-
matis IgG and IgM).
The overall prevalence of Chlamydial (past and current)
infection as detected by both ELISA and Real-TM PCR in
the unexplained infertility group was 40 % (20/50) while
the prevalence in the control group was much lower of
18.2 % (all of them being only IgG sero-positive indicating
past Chlamydial infection) where none of the controls
were positive for IgM Abs or PCR positive. Real-TM PCR
identified current Chlamydial infection in 3 (6 %) of the
case group (Fig. 1), two of which were IgM positive and all
3 cases were of the secondary infertility type and this find-
ing was statistically significant (p = 0.019). The prevalence
of anti-C.trachomatis antibodies (ACTA) (IgG and IgM
Abs) in the unexplained infertility population was 19/50
(38 %). Only three (6.0 %) cases were seropositive for IgMFig. 1 Graphical representation of real-time PCR data. Rn is the fluorescenc
reference dye; i.e., Rn is the reporter signal normalized to the fluorescence
the variation of log (ΔRn) with PCR cycle number and as seen in the figureAbs of which 2 were also IgG and PCR positive (Table 2).
The mean ratio for anti -Chlamydia trachomatis anti-
bodies (ACTA) of IgG type was 1.26 ± 0.99 (range: 0.4 -
4.3) while the mean ratio for the IgM type was 0.37 ±
0.26 (range: 0- 1.4) where a ratio <0.9 was considered
negative and > 1.1 considered positive. Eight cases had
IgG ratios >2 indicating higher levels of circulating anti-
C.trachomatis IgG. Equivocal results for IgG (with ratio =
0.9-1.1) were found in three cases (6 %) (Table 2).
Regarding the unexplained group, anti- C.trachomatis
IgM was found in the serum of 2.0/14 (14.3 %) of the
secondary infertile women and in 1.0/36 (2.8 %) of the pri-
mary type and this difference was statistically non-
significant (p = 0.186). The presence of IgM Abs did not
seem to be statistically related to the duration of infertility
(Table 2).
The majority of cases positive for IgG: 14/18 (77.8 %)
were of the primary type of unexplained infertility. Thise of the reporter dye divided by the fluorescence of a passive
signal of ROX™. The figure demonstrate an amplification plot that show
there are three positive cases that are above the threshold cycle (ct)
Table 2 Prevalence of Anti-C.trachomatis antibodies (IgG and IgM) in the serum of unexplained infertility cases in relation to the
type and duration of infertility
Anti-C.trachomatis
antibodies
Type of infertility Total (n = 50) Duration of infertility
1ry (n = 36) 2ry (n = 14) <5 years (n = 26) >5 years (n = 24)
Data presented with frequency (%)
IgM + ve 1.0 (2.8 %) 2.0 (14.3 %) 3.0 (6 %) 2.0 (7.7 %) 1.0 (2.9 %)
IgM-ve 35 (97.2 %) 12 (85.7 %) 47 (94 %) 24 (92.3 %) 34 (97.1 %)
IgG + ve 14 (38.9 %) 4.0 (28.6 %) 18 (36 %) 9.0 (34.6 %) 9.0 (25.7 %)
IgG –ve 19 (52.7 %) 10 (71.4 %) 29 (58 %) 15 (57.6 %) 24 (68.6 %)
Equivocal IgG 2.0 (5.6 %) 1.0 (7.1 %) 3.0 (6 %) 2.0 (7.7 %) 2.0 (5.7 %)
The mean ratios for anti-C.trachomatis IgG and IgM using the ELISA technique.
Data presented with mean ± S.D P p
Ratio of IgG* 1.29 ± 1.0 1.19 ± 1.0 0.63 1.22 ± 0.9 1.31 ± 1.0 0.52
Ratio of IgM* 0.37 ± 0.2 0.42 ± 0.3 0.52 0.38 ± 0.2 0.37 ± 0.2 0.42
*Values are expressed in terms of mean ± S.D.; p-value, ratios >1.1 considered positive and <0.9 considered negative
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study group. While 22.2 % of the seropositive IgG were of
the secondary type representing 28.6 % of total number of
secondary infertility cases, however this relation was
found to be statistically non-significant (p-value = 0.744).
The presence of current Chlamydial infection did not
seem to be related to the duration of unexplained infertil-
ity as shown in (Table 3). Real-time PCR was confirmatory
of current Chlamydial infection in 6 % of women with un-
explained infertility, all 3 positive cases were of the sec-
ondary infertility type and this finding was statistically
significant (p = 0.019).
Anti-sperm antibodies (ASA) were detected in three
(6 %) of the unexplained cases. Only 1 case with positive
ASA was also seropositive for IgG Abs (ratio = 1.2) indi-
cating past Chlamydial infection and 1 case had an
equivocal result for IgG Abs (ratio = 0.9). None of the
cases with current Chlamydia infection had ASA (Table 4).
In the control group,only 1/44 was positive for antisperm
antibodies (2.3 %) which was seronegative for IgG and
IgM Abs; leading to a statistically non-significant differ-
ence between case and control group(p = 0.372) (Table 1).Discussion
Chlamydia screening programs aims to reduce the mor-
bidity from upper genital tract complications and the
prevalence of the disease by controlling its transmissionTable 3 Prevalence of current genital C.trachomatis infection by PC
using the PCR technique
Type of infertility
1ry 2ry
Ct PCR + ve (n = 3) 0.0 (0 %) 3 .0 (21 %)
Ct PCR-ve (n = 47) 36 (100 %) 11 (79 %)[18]. Furthermore, pre-existing asymptomatic infections
can be disseminated when infertile patients undergoes
uterine instrumentation for further evaluation and treat-
ment of their fertility problem. Hence, the Royal College
of Obstetricians and Gynecologists recommends that all
patients undergoing uterine instrumentation should be
screened for Chlamydia spp. or should receive prophylac-
tic antibiotics [19].
This study was conducted on a randomly selected group
of women with unexplained infertility seeking ICSI/IVF,
aiming to detect the prevalence of Chlamydial infection
using ELISA for detection of anti-C.trachomatis IgG and
IgM and Real-TM PCR for Chlamydial antigen detection.
We then included a control group of infertile women with
a known cause of infertility (excluding tubal factor or pel-
vic pathology), when we were faced with the high preva-
lence in the first selected group.
The prevalence of Chlamydia genital infection and other
sexually transmitted diseases in Egypt and most Arab
countries is not exactly known, reflecting the limited spe-
cific diagnosis and treatment programmes. Various small
studies from different countries report different level of C.
trachomatis; United Arab Emirates (2.6 %) [20], Jordan
(3.9 %) [21], Qatar (5.3 %) [22], and Saudi Arabia (15 %)
[23]. This variation in prevalence is related to age of the
participants, population studied, as well as the different
methodologies used. Alarmingly, in our study population
of unexplained infertility cases, the overall prevalence of C.R in the unexplained group in relation to type and duration
Infertility duration
P <5 years ≥5 years p
0.019 1.0 (4.0 %) 2.0 (8.0 %) 0.602
25 (96 %) 22 (92 %)
Table 4 Relationship between ASA and current genital
C. trachomatis infection by PCR and anti-C. trachomatis IgG
antibodies
Chlamydial Ag by PCR Anti-C. trachomatis IgG equivocal
+ve -ve +ve -ve
ASA
+ve 0.0 3.0 (6 %) 1.0 (6.0 %) 1.0 (3.0 %) 1.0 (33 %)
-ve 3.0 47 (94 %) 17 (94 %) 28 (97 %) 2.0 (67 %)
Total 3.0 50 18 29 3.0
ASA: Antisperm antibodies
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18.2 % was detected in the control group, where none of
the cases showed evidence of recent chlamydial infection
in terms of IgM seropositivity or PCR., Al-Ramahi et al.
studied the Chlamydia prevalence through PCR only, on
152 infertile Jordanian women, and showed a prevalence of
current Chlamydia infection similar to ours of 3.9 % [21].
However, when considering only the patients with unex-
plained infertility in their studied group (66/152), the
prevalence varied to 3 % where only 2/66 were PCR + ve.
This slightly lower ratio of detection may be related to
the technique of PCR where they used the conventional
type. The authors further explained that the low preva-
lence may be attributed to social and cultural conserva-
tive nature of the Jordanian society regarding free
sexual relations [21].
A meta-analysis performed in 2002 concluded that
DNA amplification techniques performed best for both
urine and swabs in low prevalence populations [24]. Two
systematic reviews found that the use of an endocervical
swab gave greater sensitivity than first void urine with
sPCR and BD Probetec [25, 26]. In the current study we
elected to use Real-TM PCR analysis of endocervical
swabs since it is easier to perform, faster, more accurate. It is
also performed in a closed system, and as such is less prone
to contamination than conventional PCR. Furthermore,
when coupled with an automated DNA extraction method,
Real-TM PCR made it possible to process a large number of
specimens in an almost fully automated procedure, with a
low requirement for laboratory technician time [27].
There is a close correlation between the presence of
anti-Chlamydia antibodies in females and tubal factor
infertility. Antibody testing for anti-Chlamydia anti-
bodies has been found to be associated with tubal factor
of infertility. Increasingly high titers of anti-Chlamydial
IgG and anti- CHSP60 antibodies have been correlated
with increasing severity of tubal damage when evaluated
using HSG or laparoscopy [28]. The sensitivity and spe-
cificity of Chlarnydia IgG antibody test (CAT) are com-
parable to that of HSG alone. In addition CAT is less
cost prohibitive than PCR and has less risks than either
HSG or laparoscopy [29, 30].In spite of high prevalence of Chlamydial seropostivity
(38 %) among the unexplained group in the present
study, relationship to infertility is not clear since patients
do not show any signs or symptoms suggestive of pelvic
inflammatory disease and have normal tubal patency on
investigations. However, occult damage of the tubal cilia
or mucosa could not be ruled out. Additionally, infection
could have been limited to the lower genital tract only.
Moreover, mainly persistent C. trachomatis infections,
rather than cleared infections, are associated with an
increased risk of tubal pathology [28, 31, 32].
In addition, past infection with C.trachomatis did not
seem to leave a deleterious impact on the control group
(accounting for an 18 % prevalence), where none of the
women gave history of PID or showed evident tubal/pelvic
pathology or affection on diagnostic investigations per-
formed. However still, it can't be determined whether this
old infection could add to the already existing cause of
infertility in such women later on, or could be implicated
perhaps through subtle endometritis or subclinical salpin-
gitis, which necessitates close follow up of such infertile
women after possible treatment of the currently apparent
cause of infertility.
It has been hypothesized that Chlamydial infection may
impair fertility through the generation of anti-sperm anti-
bodies (ASA) as a part of the inflammatory response, which
in turn may impair sperm migration and/or block sperm-
ovum interaction [33–35]. Also, it has been proposed that
there may be an existing cross-reactivity between antigens
of Chlamydia trachomatis and spermatozoa [36–38]. In
the current study no relationship was found between past
or current C. trachomatis infection and ASA in women
with unexplained infertility. This indicates that chlamydial
infections have a low probability of inducing circulating
anti-sperm antibodies in women. Similar results were
reached in the study of Siam and Hefzy [39].
The limitations of the data surveyed in this study
include its restriction to the tertiary referral infertility
unit, the time frame of 6 month due to the expense of
PCR kits, and to a specific risk group.
Conclusion
We documented higher than expected C trachomatis
prevalence reflecting lack of STI-specific programmes
in Egypt. Review of these data led to a change of the
pre IVF workup policy in our unit, with the intro-
duction of Chlamydia serological screening and anti-
biotic treatment of positive cases. We hope to use the
results of this study to help design and complete larger
clinical trials involving the use of endometrial curett-
ings for the detection of Chlamydial antigen by DNA
amplification. This may lead to improved identification
and characterization of this subgroup of women whose
infertility is currently unexplained.
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